Vis enkel innførsel

dc.contributor.authorGansmo, Liv Beathe
dc.contributor.authorKnappskog, Stian
dc.contributor.authorRomundstad, Pål Richard
dc.contributor.authorHveem, Kristian
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorLønning, Per Eystein
dc.date.accessioned2015-06-29T13:15:47Z
dc.date.accessioned2016-06-02T10:41:42Z
dc.date.available2015-06-29T13:15:47Z
dc.date.available2016-06-02T10:41:42Z
dc.date.issued2015
dc.identifier.citationInternational Journal of Cancer 2015, 137(1):96-103nb_NO
dc.identifier.issn1097-0215
dc.identifier.urihttp://hdl.handle.net/11250/2391185
dc.description.abstractMDM2 is a key regulator of the p53 tumor suppressor protein and is overexpressed in many human cancers. Two single nucleotide polymorphisms (SNPs) located in the MDM2 intronic promoter (P2) have been found to exert biological function. The G-allele of SNP309T>G; rs2279744 increases MDM2 transcription and has been linked to increased cancer risk. In contrast, the less frequent SNP285G>C; rs117039649, which is in complete linkage disequilibrium with SNP309 (generating a SNP285C/309G variant haplotype), has been related to reduced MDM2 transcription and to reduced risk of breast, endometrial and ovarian cancer. In this large population-based case–control study, we genotyped SNP309 and SNP285 in 10,830 individuals, including cases with cancer of the breast (n=1,717), colon (n=1,532), lung (n=1,331) and prostate (n=2,501), as well as 3,749 non-cancer controls. We found a slightly reduced risk for lung cancer among individuals harboring the SNP309TG/GG genotypes compared to the SNP309TT genotype (OR= 0.86; CI = 0.67–0.98), but this association was restricted to women (OR = 0.77; CI = 0.63–0.95) and was not present among men (OR = 0.91; CI = 0.77–1.08). Consistent with previous findings, we found a reduced risk for breast cancer among individuals carrying the SNP285GC/309GG genotype versus the SNP285GG/309GG genotype (OR = 0.55; CI = 0.33–0.93). In conclusion, our data support the hypothesis that the effects of both SNP285 and SNP309 status are tissue dependent.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.relation.urihttp://onlinelibrary.wiley.com/doi/10.1002/ijc.29358/pdf
dc.rightsNavngivelse-Ikkekommersiell 3.0 Norge*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/no/*
dc.titleInfluence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colonnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.date.updated2015-06-29T13:15:47Z
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762nb_NO
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Oncology: 762nb_NO
dc.source.pagenumber96-103nb_NO
dc.source.volume137nb_NO
dc.source.journalInternational Journal of Cancernb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1002/ijc.29358
dc.identifier.cristin1203426
dc.description.localcode© 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposesnb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 3.0 Norge
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 3.0 Norge